IM
MBDP
CS
OI
CS
PCPersonalised emails written for every contact · 97% deliverability · live in 60 seconds
| Company | What they do | Location | Size | Hiring |
|---|---|---|---|---|
C4Therapeuticsc4therapeutics.com ME IMMB |
C4 Therapeutics (C4T, Nasdaq: CCCC) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicine | Watertown, Massachusetts | 51-200 | — |
Arvinasarvinas.com ZCGZ  KM |
Arvinas is a clinical-stage biotechnology company developing targeted protein degradation (PROTAC) therapeutics to degrade disease | New Haven, Connecticut | 201-1000 | — |
Kymera Therapeuticskymeratx.com VSSV  GN |
Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation (TPD) to develop oral small | Watertown, Massachusetts | 201-1000 | — |
Monterosatxmonterosatx.com  FJ RNTW |
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medici | Boston, Massachusetts | 201-1000 | — |
Cullinan Therapeuticscullinantherapeutics.com  KRZC ST |
Cullinan Therapeutics (Nasdaq: CGEM) is a clinical-stage biopharmaceutical company developing disease-modifying T cell engager the | Cambridge, Massachusetts | 51-200 | — |
Kinnate Biopharma Inc.kinnate.com  SWXG |
Kinnate Biopharma Inc. is a clinical-stage precision oncology company developing targeted cancer medicines for patients with oncog | San Diego, California | 1-10 | — |
QED Therapeuticsqedtx.com |
QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders, founded in 2018 and headquart | Palo Alto, California | 11-50 | — |
Acrivonacrivon.com JT  K( MM |
Acrivon is a clinical-stage precision oncology company developing targeted cancer therapies matched to patients via its AP3 patien | Cambridge, Massachusetts | 51-200 | — |
InduProinduprotx.com PRCSJG |
InduPro is a biotechnology company developing proximity-based therapeutics by defining and manipulating protein interactions at th | Seattle, Washington | 51-200 | — |
Boundless Bioboundlessbio.com  APAB TP |
Boundless Bio is a clinical-stage precision oncology company developing ecDNA-directed therapies (ecDTx) — novel cancer medicines | San Diego, California | 11-50 | — |
Riva Therapeuticsrivatherapeutics.com |
Riva Therapeutics is a precision oncology company developing small molecule cancer therapies that selectively target essential tum | San Diego, California | 1-10 | — |
Constellation Pharmaceuticalsconstellationpharma.com |
Constellation Pharmaceuticals is a biotechnology company developing drugs in the field of epigenetics, focusing on selective regul | Boston, Massachusetts | 51-200 | — |
Captor Therapeuticscaptortherapeutics.com  RKASAR |
Captor Therapeutics is a publicly-listed biopharmaceutical company (WSE:CTX) developing targeted protein degradation (TPD) therape | Wrocław, Dolnośląskie | 51-200 | — |
| Run live for more | ||||
C4 Therapeutics (C4T, Nasdaq: CCCC) is a clinical-stage biopharmaceutical company developing targeted protein degradation medicines that degrade disease-causing proteins using its TORPEDO platform, with a lead oncology program in clinical studies and a collaboration with Roche on degrader-antibody conjugates.
Companies like C4 Therapeutics, Inc. include Arvinas, Kymera Therapeutics, Monterosatx, Cullinan Therapeutics, Kinnate Biopharma Inc.. See the full list of 24 competitors and alternatives above.
C4 Therapeutics, Inc. has approximately 51-200 employees and is in the Biotechnology industry.
C4 Therapeutics, Inc. is headquartered in Watertown, Massachusetts.
C4 Therapeutics, Inc. operates in the Biotechnology industry.
Key decision-makers and buying contacts at C4 Therapeutics, Inc. are listed above, including leaders across executive, finance, sales and operations.